Skip to main content
Erschienen in:

01.08.2007 | Leitthema

Neue technologische Aspekte bei der Bestrahlung des Prostatakarzinoms

Bildgeführte und intensitätsmodulierte Bestrahlungstechniken

verfasst von: Dr. U. Ganswindt, M. Bamberg, C. Belka

Erschienen in: Die Onkologie | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Obwohl die Strahlentherapie schon jetzt eine sichere und nebenwirkungsarme Behandlungsform des Prostatakarzinoms darstellt, ist durch verschiedene technologische Verbesserungen eine weitere Optimierung in der Zukunft zu erwarten. Insbesondere kann durch einen weitflächigen Einsatz von intensitätsmodulierten Bestrahlungstechniken (IMRT) eine optimierte Schonung von umgebenden Normalgeweben bei besserer Erfassung der Zielvolumina erreicht werden. Die optimierte Normalgewebsschonung mittels IMRT verlangt aber nach präziseren Visualisierungsverfahren der Lagerung. Techniken wie das Cone-Beam-CT, implantierte Goldmarker oder Radiotransponder wie auch ultraschallbasierte Lagerungskontrollen stellen technische Lösungsansätze dar. Darüber hinaus zeichnet es sich ab, dass die Integration verschiedener Bildgebungsmodalitäten (MRT, MR-Spektroskopie, PET-CT, SPECT-Sentineldarstellung) in den Prozess der Bestrahlungsplanung zu einer Präzisierung der Zielvolumendefinition führen kann. Bislang liegen für fast alle der genannten Ansätze nur Studien vor, die eine klinische Machbarkeit validieren. Dennoch ist klar, dass die neuen technologischen Ansätze zu einem weiten Teil ihren Eingang in die Routinetherapie bei der Bestrahlung des Prostatakarzinoms finden werden.
Literatur
1.
Zurück zum Zitat Ganswindt U, Paulsen F, Anastasiadis AG et al. (2005) 70 Gy or more:which dose for which prostate cancer? J Cancer Res Clin Oncol 131:407–419PubMedCrossRef Ganswindt U, Paulsen F, Anastasiadis AG et al. (2005) 70 Gy or more:which dose for which prostate cancer? J Cancer Res Clin Oncol 131:407–419PubMedCrossRef
2.
Zurück zum Zitat Pollack A, Zagars GK, Starkschall G et al. (2002) Prostate cancer radiation dose response:results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105PubMedCrossRef Pollack A, Zagars GK, Starkschall G et al. (2002) Prostate cancer radiation dose response:results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105PubMedCrossRef
3.
Zurück zum Zitat Storey MR, Pollack A, Zagars G et al. (2000) Complications from radiotherapy dose escalation in prostate cancer:preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48:635–642PubMedCrossRef Storey MR, Pollack A, Zagars G et al. (2000) Complications from radiotherapy dose escalation in prostate cancer:preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48:635–642PubMedCrossRef
4.
Zurück zum Zitat Peeters ST, Heemsbergen WD, Koper PC et al. (2006) Dose-response in radiotherapy for localized prostate cancer:results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996PubMedCrossRef Peeters ST, Heemsbergen WD, Koper PC et al. (2006) Dose-response in radiotherapy for localized prostate cancer:results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996PubMedCrossRef
5.
Zurück zum Zitat Bolla M, Collette L, Blank L et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106PubMedCrossRef Bolla M, Collette L, Blank L et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106PubMedCrossRef
6.
Zurück zum Zitat Roach M 3rd, DeSilvio M, Lawton C et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911PubMedCrossRef Roach M 3rd, DeSilvio M, Lawton C et al. (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21:1904–1911PubMedCrossRef
7.
Zurück zum Zitat Lawton CA, De Silvio M, Roach M 3rd, Uhl V et al. (2005) An update of the phase III trial comparing whole-pelvic to prostate only radiotherapy and neoadjuvant total androgen suppression: Updated analysis of RTOG 94–13. Int J Radiat Oncol Biol Phys (Supp 1) 63:S19CrossRef Lawton CA, De Silvio M, Roach M 3rd, Uhl V et al. (2005) An update of the phase III trial comparing whole-pelvic to prostate only radiotherapy and neoadjuvant total androgen suppression: Updated analysis of RTOG 94–13. Int J Radiat Oncol Biol Phys (Supp 1) 63:S19CrossRef
8.
Zurück zum Zitat Roach M 3rd, DeSilvio M, Valicenti R et al. (2006) Whole-pelvis, „mini-pelvis,“ or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66:647–653PubMed Roach M 3rd, DeSilvio M, Valicenti R et al. (2006) Whole-pelvis, „mini-pelvis,“ or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 66:647–653PubMed
9.
Zurück zum Zitat Ashman JB, Zelefsky MJ, Hunt MS et al. (2005) Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63:765–771PubMedCrossRef Ashman JB, Zelefsky MJ, Hunt MS et al. (2005) Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63:765–771PubMedCrossRef
10.
Zurück zum Zitat De Meerleer GO, Vakaet LA, De Gersem WR et al. (2000) Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 47:639–648CrossRef De Meerleer GO, Vakaet LA, De Gersem WR et al. (2000) Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 47:639–648CrossRef
11.
Zurück zum Zitat Jani AB, Gratzle J, Correa D (2007) Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer. Technol Cancer Res Treat 6:11–15PubMed Jani AB, Gratzle J, Correa D (2007) Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer. Technol Cancer Res Treat 6:11–15PubMed
12.
Zurück zum Zitat Zelefsky MJ, Fuks Z, Hunt M et al. (2002) High-dose intensity modulated radiation therapy for prostate cancer:early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116PubMedCrossRef Zelefsky MJ, Fuks Z, Hunt M et al. (2002) High-dose intensity modulated radiation therapy for prostate cancer:early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116PubMedCrossRef
13.
Zurück zum Zitat Zelefsky MJ, Chan H, Hunt M et al. (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419PubMedCrossRef Zelefsky MJ, Chan H, Hunt M et al. (2006) Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176:1415–1419PubMedCrossRef
14.
Zurück zum Zitat Ganswindt U, Paulsen F, Corvin S et al. (2007) Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 67:347–355PubMed Ganswindt U, Paulsen F, Corvin S et al. (2007) Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique. Int J Radiat Oncol Biol Phys 67:347–355PubMed
15.
Zurück zum Zitat Wang-Chesebro A, Xia P, Coleman J et al. (2006) Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66:654–662PubMed Wang-Chesebro A, Xia P, Coleman J et al. (2006) Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66:654–662PubMed
16.
Zurück zum Zitat Nutting CM, Convery DJ, Cosgrove VP et al. (2000) Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48:649–656PubMedCrossRef Nutting CM, Convery DJ, Cosgrove VP et al. (2000) Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys 48:649–656PubMedCrossRef
17.
Zurück zum Zitat Zelefsky MJ, Crean D, Mageras GS et al. (1999) Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol 50:225–234PubMedCrossRef Zelefsky MJ, Crean D, Mageras GS et al. (1999) Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol 50:225–234PubMedCrossRef
18.
Zurück zum Zitat Antolak JA, Rosen II, Childress CH et al. (1998) Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys 42:661–672PubMedCrossRef Antolak JA, Rosen II, Childress CH et al. (1998) Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys 42:661–672PubMedCrossRef
19.
Zurück zum Zitat Chung PW, Haycocks T, Brown T et al. (2004) On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 60:329–334PubMedCrossRef Chung PW, Haycocks T, Brown T et al. (2004) On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 60:329–334PubMedCrossRef
20.
Zurück zum Zitat Fung AY, Enke CA, Ayyangar KM et al. (2005) Prostate motion and isocenter adjustment from ultrasound-based localization during delivery of radiation therapy. Int J Radiat Oncol Biol Phys 61:984–992PubMedCrossRef Fung AY, Enke CA, Ayyangar KM et al. (2005) Prostate motion and isocenter adjustment from ultrasound-based localization during delivery of radiation therapy. Int J Radiat Oncol Biol Phys 61:984–992PubMedCrossRef
21.
Zurück zum Zitat Dobler B, Mai S, Ross C et al. (2006) Evaluation of possible prostate displacement induced by pressure applied during transabdominal ultrasound image acquisition. Strahlenther Onkol 182:240–246PubMedCrossRef Dobler B, Mai S, Ross C et al. (2006) Evaluation of possible prostate displacement induced by pressure applied during transabdominal ultrasound image acquisition. Strahlenther Onkol 182:240–246PubMedCrossRef
22.
Zurück zum Zitat Wong JR, Grimm L, Uematsu M et al. (2005) Image-guided radiotherapy for prostate cancer by CT-linear accelerator combination:prostate movements and dosimetric considerations. Int J Radiat Oncol Biol Phys 61:561–569PubMedCrossRef Wong JR, Grimm L, Uematsu M et al. (2005) Image-guided radiotherapy for prostate cancer by CT-linear accelerator combination:prostate movements and dosimetric considerations. Int J Radiat Oncol Biol Phys 61:561–569PubMedCrossRef
23.
Zurück zum Zitat Kupelian P, Willoughby T, Mahadevan A et al. (2007) Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 67:1088–1098PubMed Kupelian P, Willoughby T, Mahadevan A et al. (2007) Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 67:1088–1098PubMed
24.
Zurück zum Zitat Roach M 3rd, Faillace-Akazawa P, Malfatti C et al. (1996) Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 35:1011–1018PubMedCrossRef Roach M 3rd, Faillace-Akazawa P, Malfatti C et al. (1996) Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 35:1011–1018PubMedCrossRef
25.
Zurück zum Zitat Rasch C, Barillot I, Remeijer P et al. (1999) Definition of the prostate in CT and MRI:a multi-observer study. Int J Radiat Oncol Biol Phys 43:57–66PubMed Rasch C, Barillot I, Remeijer P et al. (1999) Definition of the prostate in CT and MRI:a multi-observer study. Int J Radiat Oncol Biol Phys 43:57–66PubMed
26.
Zurück zum Zitat Kurhanewicz J, Vigneron DB, Hricak H et al. (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 198:795–805PubMed Kurhanewicz J, Vigneron DB, Hricak H et al. (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 198:795–805PubMed
27.
Zurück zum Zitat Kurhanewicz J, Vigneron DB, Nelson SJ (2000) Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2:166–189PubMedCrossRef Kurhanewicz J, Vigneron DB, Nelson SJ (2000) Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2:166–189PubMedCrossRef
28.
Zurück zum Zitat Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990–995PubMed Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990–995PubMed
29.
Zurück zum Zitat Vees H, Buchegger F, Albrecht S et al. (2007) (18)F-choline and/or (11)C-acetate positron emission tomography:detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 8:8 Vees H, Buchegger F, Albrecht S et al. (2007) (18)F-choline and/or (11)C-acetate positron emission tomography:detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 8:8
30.
Zurück zum Zitat Hacker A, Jeschke S, Leeb K et al. (2006) Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer:comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176:2014–2018; discussion 2018–2019PubMedCrossRef Hacker A, Jeschke S, Leeb K et al. (2006) Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer:comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176:2014–2018; discussion 2018–2019PubMedCrossRef
31.
Zurück zum Zitat Scattoni V, Picchio M, Suardi N et al. (2007) Detection of Lymph-Node metastases with integrated [(11)C]Choline PET/CT in patients with PSA failure after radical retropubic prostatectomy:Results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 20:20 Scattoni V, Picchio M, Suardi N et al. (2007) Detection of Lymph-Node metastases with integrated [(11)C]Choline PET/CT in patients with PSA failure after radical retropubic prostatectomy:Results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 20:20
32.
Zurück zum Zitat Reske SN, Blumstein NM, Neumaier B et al. (2006) Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47:1249–1254PubMed Reske SN, Blumstein NM, Neumaier B et al. (2006) Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47:1249–1254PubMed
33.
Zurück zum Zitat Weckermann D, Dorn R, Trefz M et al. (2007) Sentinel lymph node dissection for prostate cancer:experience with more than 1,000 patients. J Urol 177:916–920PubMedCrossRef Weckermann D, Dorn R, Trefz M et al. (2007) Sentinel lymph node dissection for prostate cancer:experience with more than 1,000 patients. J Urol 177:916–920PubMedCrossRef
Metadaten
Titel
Neue technologische Aspekte bei der Bestrahlung des Prostatakarzinoms
Bildgeführte und intensitätsmodulierte Bestrahlungstechniken
verfasst von
Dr. U. Ganswindt
M. Bamberg
C. Belka
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-007-1227-7

Weitere Artikel der Ausgabe 8/2007

Der Onkologe 8/2007 Zur Ausgabe

CME Weiterbildung • Zertifizierte Fortbildung

Kutanes Melanom

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.